KDR and neoplasm: Anti-vascular endothelial growth factor receptor (anti-VEGFR) pioneered the attempts to normalize tumor vasculature and restore its function, as indicated by tissue perfusion and decreasing intratumoral hypoxia, and fostered further investigations aimed at shaping the intratumoral immune cell phenotype in parallel with vascular normalization [23], while polarizing macrophages throughout and M1 gene-expression phenotype, paralleling an increase in adaptive immune cells’ infiltration in the setting of this antiangiogenic treatment [23,60].